Pharmaceutical Technology E-Alert:
Having trouble viewing this e-mail? Click here.
  Pharmaceutical Technology Europe E-Alert
 
24 August 2012

IN THIS ISSUE
Gene patenting
GSK divests products
Defrauding FDA
Eli Lilly receives payment
LinkedIn


Myriad Wins Gene Patent Ruling
A US federal appeals court has ruled that Myriad Genetics’ composition of matter claims covering isolated DNA of the BRCA 1 and BRCA 2 genes are patent-eligible material under federal patent law. More...
 
GlaxoSmithKline Divests Brands in Australia for $271 million
GlaxoSmithKline (GSK) is selling the majority of its ‘classic brands’ in Australia to Aspen Global for approximately £172 million in cash. More...
 
Grey-Market Distributor Convicted of Defrauding FDA
US-based Altec Medical has pleaded guilty to conspiring to defraud FDA and to commit federal offenses in connection with a drug-diversion scheme that lasted from 2007 to 2009. More...
 
Eli Lilly Receives $1.3 Billion From Amylin Pharmaceuticals
Eli Lilly has received $1.3 billion for payment of financial obligations from Amylin Pharmaceuticals following Bristol-Myers Squibb’s acquisition of Amylin Pharmaceuticals earlier this month. More...
 
Join our community on LinkedIn
Want to discuss any of this week's news stories or any other hot topics in the industry? Then why not join our group on LinkedIn? More...
Key Topics:

Latest blog posts
Silicon Meets Biology
How to Prepare a Deviation Investigation Report
Federal Judge Moves Forward with Meningococcal Vaccine Antitrust Suit against Sanofi
More blog posts

Latest articles
Measuring Growth in Big Pharma's Manufacturing Investment
Bioavailability Enhancement: When to Use Hot-Melt Extrusion versus Spray Drying
Report from Japan
More articles

Upcoming events
2012 PDA FDA Joint Regulatory Conference (10–12 September | US)
European Downstream Technology Forum (11–12 September | Germany)
World Drug Safety Congress Europe 2012 (11–13 September | UK)
More events

Products/Service Profiles
Agilent

Realize Effective Pharmaceuticals
Reliable solutions enable pharmaceutical scientists to innovate in disease research, accelerate drug discovery and have greater confidence throughout development and manufacturing. Agilent solutions in genomics research, automation, separation and detection technologies along with workflow driven software solutions helps deliver the answers to bring effective therapeutics to market.
Learn about pharmaceutical purification, purity, and impurity analyses at www.agilent.com/lifesciences/realizepharma

 
Agilent

Advances in Label-Free Technology (Video) – Click to Watch
Watch this customer success story as told by GSK in this video. Learn how you too can unlock challenging targets, simplify assay design, and shorten time to results with the Agilent RapidFire System. In this video, GSK presents the findings from their studies using the RapidFire High-throughput Mass Spectrometry System in various stages of the lead discovery process.
Re-Imagine Mass Spectrometry Throughput Watch the video

Survey
Do you think large drug settlements to settle criminal and civil liabilities are an appropriate deterrent to corporate malpractices such as unlawful promotion of drugs and failure to report safety data?
 
Yes 76%
 
 
No 24%

This week we would like to know...

Has your company started implementing procedures and practices required by Europe's new pharmacovigilance legislation?

Click here to vote

Contact Us
Click here to contact editorial.

Click here to contact sales.